Global Ankylosing Spondylitis Treatment Market Report and Forecast 2023-2031

The ankylosing spondylitis treatment market size is being driven by the increasing prevalence of the condition and the growing investment in research and development activities. The market was estimated to be worth USD 4.64 billion in 2022. The market is anticipated to grow at a CAGR of 8.1% during the forecast period of 2023-2031 to reach USD 9.37 billion by 2031.

Ankylosing Spondylitis Treatment Market: Introduction

Ankylosing spondylitis is a type of arthritis that affects the joints of the spine. The disease causes inflammation in the joints and can lead to chronic pain, stiffness, and the eventual fusion of the spine. There is currently no cure for ankylosing spondylitis but there are various treatment options available in the market that aim to manage the symptoms of the disease. The report covers the market for ankylosing spondylitis treatment, including drugs and therapies, and provides a detailed analysis of the market size, growth, and trends.

Ankylosing Spondylitis Epidemiology

Ankylosing spondylitis is a chronic autoimmune disease that affects approximately 0.1% to 1% of the global population. The disease is more common in men than in women, with a male-to-female ratio of approximately 2:1. The disease typically begins in young adulthood and can progress over time, leading to chronic pain, stiffness, and the eventual fusion of the spine.

Ankylosing spondylitis is a chronic inflammatory disorder that affects the spine and sacroiliac joints. The exact cause of the disease is unknown but it is believed to be a combination of genetic and environmental factors. The disease is more common in men than women, and typically affects individuals in their late teens to early 30s.

The treatment options for ankylosing spondylitis are focused on reducing inflammation, managing pain and stiffness, and improving mobility. Nonsteroidal anti-inflammatory drugs (NSAIDs) and biologic agents are commonly used to manage the symptoms of the disease. Physical therapy, exercise, and other forms of rehabilitation are also important components of treatment.

Ankylosing Spondylitis Treatment Market Segmentations

The market can be categorised into drug type, indication type, treatment method, treatment channel, and major regions.

Market Breakup by Drug Type

• Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
• Disease-Modifying Anti-Rheumatic Drugs (DMARDs)
• Tumour Necrosis Factor (TNF) Inhibitors
• Interleukin (IL) Inhibitors
• Others

Market Breakup by Indication Type

• Medication
• Reactive Arthritis
• Psoriatic Arthritis
• IBD Associated Arthritis
• Juvenile Spondyloarthropathy
• Undifferentiated Spondyloarthropathy
• Others

Market Breakup by Treatment Method

• Physiotherapy and Exercise
• Painkillers
• Biological Treatments
• Corticosteroids
• Disease Modifying Anti Rheumatic Drugs (DMARDs)
• Surgery
• Others

Market Breakup by Treatment Channel

• Medication
• Public
• Private

Ankylosing Spondylitis Treatment Market Breakup by Region

North America

• United States of America
• Canada

Europe

• United Kingdom
• Germany
• France
• Italy
• Others

Asia Pacific

• China
• Japan
• India
• ASEAN
• Australia
• Others

Latin America

• Brazil
• Argentina
• Mexico
• Others

Middle East and Africa

• Saudi Arabia
• United Arab Emirates
• Nigeria
• South Africa
• Others

Ankylosing Spondylitis Treatment Market Scenario

The global ankylosing spondylitis treatment market is expected to grow at a significant rate during the forecast period of 2023-2031. The increasing prevalence of the disease, growing awareness, and advancements in medical technology are the key drivers of the market. North America dominates the market, followed by Europe and Asia Pacific. The leading players in the market are focusing on the development of new drugs and therapies and adopting various strategies to strengthen their position in the market.

North America dominates the ankylosing spondylitis treatment market, followed by Europe and Asia Pacific. The high prevalence of ankylosing spondylitis in North America, coupled with the favourable reimbursement policies, is driving the growth of the market in the region. Europe is also a significant market for ankylosing spondylitis treatment, with the presence of key players and increasing investment in research and development activities. The Asia Pacific region is expected to grow at the highest CAGR during the forecast period, owing to the increasing awareness about the disease and the rising healthcare expenditure in the region.

Key Players in the Global Ankylosing Spondylitis Treatment Market

The report gives an in-depth analysis of the key players involved in the ankylosing spondylitis treatment market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:

• AbbVie Inc
• Amgen Inc
• Gilead Sciences
• Eli Lilly and Company
• Johnson & Johnson
• Novartis AG
• Pfizer Inc